MindWave Innovations Announces $NILA Token Listing on PICOL Platform
MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., has launched trading for its $NILA token on the South Korean platform PICOL.
Stocks · News reference
MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc., has signed a joint venture agreement with Skalup Capital to launch a Bermuda-based insurance and technology business.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., has launched trading for its $NILA token on the South Korean platform PICOL.
MindWave Innovations, a subsidiary of Apimeds Pharmaceuticals US, Inc., is providing the technical backend for a new $25 million ecosystem credit initiative launched by AQUAE Labs.
MindWave Innovations, a subsidiary of Apimeds Pharmaceuticals US, Inc., has announced the expansion of its MindChain technology into the climate finance, sports media, and insurance sectors.
Filed: 2026-10-13 AccNo: 0001213900-26-108780 Size: 238 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US, Inc., signed three blockchain network agreements within 10 days with AQUAE Holdings (climate finance), Flash Sports & Media Holdings (sports media), and BlockAssure Inc. (insurance). Each agreement follows the same model where MindWave builds and operates dedicated MindChain networks while receiving 20% token/credit allocations. However, the parent company disclosed substantial doubt about its ability to continue as a going concern.